GHRP-6

GHRP-6 was developed in the 1980s by Bowers and colleagues as part of pioneering research into synthetic growth hormone secretagogues. It is a hexapeptide (6 amino acids) containing two non-standard D-amino acid residues — D-Tryptophan at position 2 and D-Phenylalanine at position 5 — which confer resistance to enzymatic degradation and define its receptor pharmacophore.

GHRP-6 acts as a potent agonist at the growth hormone secretagogue receptor type 1a (GHSR1a) — the ghrelin receptor — triggering strong pulsatile GH release from somatotrophs in the anterior pituitary. Unlike GHRH analogues (such as CJC-1295) which amplify the GH pulse height, GHRP-6 primarily triggers the release event itself, making them synergistic when combined.

A notable characteristic of GHRP-6 is its strong appetite-stimulating effect — a direct consequence of GHSR1a activation, which shares the same receptor as the hunger hormone ghrelin. This makes GHRP-6 particularly useful in research contexts involving muscle building, recovery, or conditions associated with low appetite and cachexia. It also significantly stimulates cortisol and prolactin release at higher doses, which distinguishes it from newer, more selective GHRPs like Ipamorelin.

// GHSR1a AGONISM — GH PULSE TRIGGERING

GHRP-6 binds the ghrelin/GHS-R1a receptor on pituitary somatotrophs with high affinity. This triggers intracellular calcium mobilization via Gq/11 signalling, directly causing GH vesicle exocytosis. Unlike GHRH (which amplifies GH pulse amplitude via cAMP), GHRP-6 acts as a release trigger — the two mechanisms are orthogonal and synergistic when combined in stacks.

// IGF-1 AXIS ELEVATION

GH released by GHRP-6 travels to the liver and peripheral tissues where it stimulates IGF-1 synthesis. Elevated IGF-1 mediates the primary anabolic and tissue repair effects attributed to GHRP-6 use: muscle protein synthesis, satellite cell activation, nitrogen retention, and connective tissue repair.

// APPETITE STIMULATION VIA GHRELIN PATHWAY

GHSR1a activation in the hypothalamic arcuate nucleus stimulates NPY/AgRP neurones, increasing orexigenic drive. This appetite effect is dose-dependent and represents GHRP-6's most pronounced side effect relative to newer GHRPs. In clinical research contexts (cachexia, post-surgical recovery), this appetite stimulation is itself a therapeutic target.

// CORTISOL & PROLACTIN CO-STIMULATION

Unlike the selective GHRP Ipamorelin, GHRP-6 also stimulates cortisol release (via ACTH) and prolactin at therapeutic doses. Cortisol rise is transient but relevant in stress-sensitive research protocols. This lack of selectivity is the primary reason Ipamorelin has supplanted GHRP-6 in most modern stacks.

GHRP-6 was instrumental in establishing the GHSR1a receptor class. Bowers et al. demonstrated in multiple human studies that GHRP-6 produces robust, dose-dependent GH pulses when administered intravenously or subcutaneously, with peak GH responses at 1–3 µg/kg. The synergy with GHRH was established in landmark studies showing that co-administration produces GH responses 3–10x greater than either agent alone.

Clinical investigations of GHRP-6 in GH-deficient adults and elderly patients showed restoration of GH pulsatility and normalization of IGF-1 levels. Appetite stimulation in cachexia models has been explored as a secondary indication.

In practice, GHRP-6 has been largely replaced by Ipamorelin in body composition research due to Ipamorelin's superior selectivity (no cortisol/prolactin spike). GHRP-6 remains relevant for appetite-stimulation protocols and as a reference compound for GHSR1a pharmacology.